$230 Million

AbSci Corporation

Initial Public Offering

Bookrunner, July 2021

AbSci Corporation

AbSci Corporation (“AbSci” or the “Company”) is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology. The Company’s AI-powered Integrated Drug Creation Platform enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. The Company leverages proprietary synthetic biology technologies and deep learning AI to predict, identify, design, construct, screen, select and scale production of novel biologic drug candidates, and learn from the data it generates. The Company believes its approach delivers disruptive efficiency, and enables its partners to create novel and human/AI-designed new-to-nature biologics (next-generation biologics).